Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans
Standard
Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans. / Agorastos, Agorastos; Demiralay, Cüneyt; Stiedl, Oliver; Muhtz, Christoph; Wiedemann, Klaus; Kellner, Michael.
In: INT CLIN PSYCHOPHARM, Vol. 31, No. 3, 05.2016, p. 176-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans
AU - Agorastos, Agorastos
AU - Demiralay, Cüneyt
AU - Stiedl, Oliver
AU - Muhtz, Christoph
AU - Wiedemann, Klaus
AU - Kellner, Michael
PY - 2016/5
Y1 - 2016/5
N2 - Group II metabotropic glutamate receptors (mGluR2/3) are suggested to modulate anxiety, arousal, and stress including autonomic control. However, no study has investigated mGluR2/3-related effects on baseline autonomic activity and reactivity to emotional challenge in humans as yet. Using a double-blind, randomized placebo-controlled, cross-over study design, we investigated the influence of a 1-week treatment with the mGluR2/3 agonist LY544344, prodrug of LY354740, on autonomic reactivity to a cholecystokinin tetrapeptide (CCK-4) panic challenge in eight healthy young men. The main outcome measures were time and frequency domain heart rate variability parameters during baseline, CCK-4 challenge, and recovery. There was no evidence for LY544344-mediated effects on baseline and CCK-4 challenge vagal activity, but a significantly lower recovery low frequency (%) and low frequency/high frequency ratio in the LY544344 group, suggesting enhanced autonomic recovery. This pilot study provides first human data indicating that mGluR2/3 agonism is involved in autonomic responsiveness, suggesting an important role of mGluR2/3 in central autonomic regulation.
AB - Group II metabotropic glutamate receptors (mGluR2/3) are suggested to modulate anxiety, arousal, and stress including autonomic control. However, no study has investigated mGluR2/3-related effects on baseline autonomic activity and reactivity to emotional challenge in humans as yet. Using a double-blind, randomized placebo-controlled, cross-over study design, we investigated the influence of a 1-week treatment with the mGluR2/3 agonist LY544344, prodrug of LY354740, on autonomic reactivity to a cholecystokinin tetrapeptide (CCK-4) panic challenge in eight healthy young men. The main outcome measures were time and frequency domain heart rate variability parameters during baseline, CCK-4 challenge, and recovery. There was no evidence for LY544344-mediated effects on baseline and CCK-4 challenge vagal activity, but a significantly lower recovery low frequency (%) and low frequency/high frequency ratio in the LY544344 group, suggesting enhanced autonomic recovery. This pilot study provides first human data indicating that mGluR2/3 agonism is involved in autonomic responsiveness, suggesting an important role of mGluR2/3 in central autonomic regulation.
KW - Adult
KW - Alanine
KW - Bridged Bicyclo Compounds
KW - Cross-Over Studies
KW - Double-Blind Method
KW - Healthy Volunteers
KW - Heart Rate
KW - Humans
KW - Male
KW - Panic
KW - Pilot Projects
KW - Receptors, Metabotropic Glutamate
KW - Tetragastrin
KW - Young Adult
KW - Journal Article
KW - Randomized Controlled Trial
KW - Research Support, Non-U.S. Gov't
U2 - 10.1097/YIC.0000000000000117
DO - 10.1097/YIC.0000000000000117
M3 - SCORING: Journal article
C2 - 26752621
VL - 31
SP - 176
EP - 178
JO - INT CLIN PSYCHOPHARM
JF - INT CLIN PSYCHOPHARM
SN - 0268-1315
IS - 3
ER -
